A Genotype-Guided Strategy for Oral P2Y
| Autor: | Daniel M F, Claassens, Gerrit J A, Vos, Thomas O, Bergmeijer, Renicus S, Hermanides, Arnoud W J, van 't Hof, Pim, van der Harst, Emanuele, Barbato, Carmine, Morisco, Richard M, Tjon Joe Gin, Folkert W, Asselbergs, Arend, Mosterd, Jean-Paul R, Herrman, Willem J M, Dewilde, Paul W A, Janssen, Johannes C, Kelder, Maarten J, Postma, Anthonius, de Boer, Cornelis, Boersma, Vera H M, Deneer, Jurriën M, Ten Berg |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Ticagrelor Genotype Coronary Thrombosis Administration Oral Hemorrhage Middle Aged Clopidogrel Intention to Treat Analysis Cytochrome P-450 CYP2C19 Percutaneous Coronary Intervention Purinergic P2Y Receptor Antagonists Humans ST Elevation Myocardial Infarction Female Single-Blind Method Stents Precision Medicine Prasugrel Hydrochloride Aged |
| Zdroj: | The New England journal of medicine. 381(17) |
| ISSN: | 1533-4406 |
| Popis: | It is unknown whether patients undergoing primary percutaneous coronary intervention (PCI) benefit from genotype-guided selection of oral P2YWe conducted a randomized, open-label, assessor-blinded trial in which patients undergoing primary PCI with stent implantation were assigned in a 1:1 ratio to receive either a P2YFor the primary analysis, 2488 patients were included: 1242 in the genotype-guided group and 1246 in the standard-treatment group. The primary combined outcome occurred in 63 patients (5.1%) in the genotype-guided group and in 73 patients (5.9%) in the standard-treatment group (absolute difference, -0.7 percentage points; 95% confidence interval [CI], -2.0 to 0.7; P0.001 for noninferiority). The primary bleeding outcome occurred in 122 patients (9.8%) in the genotype-guided group and in 156 patients (12.5%) in the standard-treatment group (hazard ratio, 0.78; 95% CI, 0.61 to 0.98; P = 0.04).In patients undergoing primary PCI, a |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|